{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:25Z","timestamp":1792784965989,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72242-w","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:24:40Z","timestamp":1778203480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-055X","authenticated-orcid":false,"given":"Padmanee","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Krainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2986-5617","authenticated-orcid":false,"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2498-402X","authenticated-orcid":false,"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Wiechno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samith","family":"Kochuparambil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 \u00c1ngel","family":"Arranz Arija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"McCune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steinbj\u00f8rn","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gedske","family":"Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Delgado Mingorance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1168-5108","authenticated-orcid":false,"given":"Craig","family":"Kukard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-7732","authenticated-orcid":false,"given":"Sumit K.","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-3833","authenticated-orcid":false,"given":"Sreyashi","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3911-6815","authenticated-orcid":false,"given":"Sonali","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-1294","authenticated-orcid":false,"given":"Bilal A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Fedorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha P.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arancha","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2113-6540","authenticated-orcid":false,"given":"Yumeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2151-605X","authenticated-orcid":false,"given":"Justin M.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-7631","authenticated-orcid":false,"given":"Russell K.","family":"Pachynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"72242_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma, P. et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell 38, 489\u2013499 e483 (2020).","journal-title":"Cancer Cell"},{"key":"72242_CR2","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","volume":"35","author":"HJ Hammers","year":"2017","unstructured":"Hammers, H. J. et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J. Clin. Oncol. 35, 3851\u20133858 (2017).","journal-title":"J. Clin. Oncol."},{"key":"72242_CR3","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020\u20132031 (2019).","journal-title":"N. Engl. J. Med."},{"key":"72242_CR4","doi-asserted-by":"publisher","first-page":"110132","DOI":"10.1016\/j.celrep.2021.110132","volume":"37","author":"ZK Tuong","year":"2021","unstructured":"Tuong, Z. K. et al. Resolving the immune landscape of human prostate at a single-cell level in health and cancer. Cell Rep. 37, 110132 (2021).","journal-title":"Cell Rep."},{"key":"72242_CR5","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700\u2013712 (2014).","journal-title":"Lancet Oncol."},{"key":"72242_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2017","unstructured":"Beer, T. M. et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-na\u00efve castration-resistant prostate cancer. J. Clin. Oncol. 35, 40\u201347 (2017).","journal-title":"J. Clin. Oncol."},{"key":"72242_CR7","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"72242_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147\u20131154 (2010).","journal-title":"Lancet"},{"key":"72242_CR9","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","volume":"35","author":"M Eisenberger","year":"2017","unstructured":"Eisenberger, M. et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg\/m2) and the currently approved dose (25 mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer\u2014PROSELICA. J. Clin. Oncol. 35, 3198\u20133206 (2017).","journal-title":"J. Clin. Oncol."},{"key":"72242_CR10","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"R de Wit","year":"2019","unstructured":"de Wit, R. et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. 381, 2506\u20132518 (2019).","journal-title":"N. Engl. J. Med."},{"key":"72242_CR11","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/jnci\/djt280","volume":"105","author":"S Halabi","year":"2013","unstructured":"Halabi, S. et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J. Natl. Cancer Inst. 105, 1729\u20131737 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"72242_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/annonc\/mdv594","volume":"27","author":"KN Chi","year":"2016","unstructured":"Chi, K. N. et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann. Oncol. 27, 454\u2013460 (2016).","journal-title":"Ann. Oncol."},{"key":"72242_CR13","doi-asserted-by":"publisher","first-page":"106468","DOI":"10.18632\/oncotarget.22474","volume":"8","author":"BPS Belderbos","year":"2017","unstructured":"Belderbos, B. P. S. et al. Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel. Oncotarget 8, 106468\u2013106474 (2017).","journal-title":"Oncotarget"},{"key":"72242_CR14","first-page":"3877","volume":"10","author":"D Dai","year":"2018","unstructured":"Dai, D. et al. Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis. Am. J. Transl. Res. 10, 3877\u20133886 (2018).","journal-title":"Am. J. Transl. Res."},{"key":"72242_CR15","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1002\/cncr.32445","volume":"125","author":"CS Higano","year":"2019","unstructured":"Higano, C. S. et al. Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. Cancer 125, 4172\u20134180 (2019).","journal-title":"Cancer"},{"key":"72242_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.clgc.2019.07.009","volume":"17","author":"K Mori","year":"2019","unstructured":"Mori, K. et al. Prognostic value of lactate dehydrogenase in metastatic prostate cancer: a systematic review and meta-analysis. Clin. Genitourin. Cancer 17, 409\u2013418 (2019).","journal-title":"Clin. Genitourin. Cancer"},{"key":"72242_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41391-020-0213-7","volume":"23","author":"O Sartor","year":"2020","unstructured":"Sartor, O. et al. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 23, 517\u2013526 (2020).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"72242_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.urolonc.2022.06.018","volume":"41","author":"T Yanagisawa","year":"2023","unstructured":"Yanagisawa, T. et al. Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: a systematic review and meta-analysis. Urol. Oncol. 41, 177\u2013191 (2023).","journal-title":"Urol. Oncol."},{"key":"72242_CR19","doi-asserted-by":"publisher","first-page":"e2142093","DOI":"10.1001\/jamanetworkopen.2021.42093","volume":"5","author":"M Marar","year":"2022","unstructured":"Marar, M. et al. Outcomes among African American and non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw. Open 5, e2142093 (2022).","journal-title":"JAMA Netw. Open"},{"key":"72242_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32, 661\u2013672 (2021).","journal-title":"Ann. Oncol."},{"key":"72242_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/pros.24110","volume":"81","author":"E Shenderov","year":"2021","unstructured":"Shenderov, E. et al. Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: a phase-2 nonrandomized clinical trial. Prostate 81, 326\u2013338 (2021).","journal-title":"Prostate"},{"key":"72242_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2021.09.043","volume":"160","author":"K Fizazi","year":"2022","unstructured":"Fizazi, K. et al. Nivolumab plus docetaxel in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur. J. Cancer 160, 61\u201371 (2022).","journal-title":"Eur. J. Cancer"},{"key":"72242_CR23","doi-asserted-by":"publisher","first-page":"e004761","DOI":"10.1136\/jitc-2022-004761","volume":"10","author":"K Fizazi","year":"2022","unstructured":"Fizazi, K. et al. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. J. Immunother. Cancer 10, e004761 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"72242_CR24","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","volume":"35","author":"S van Wilpe","year":"2024","unstructured":"van Wilpe, S. et al. Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial. Ann. Oncol. 35, 1126\u20131137 (2024).","journal-title":"Ann. Oncol."},{"key":"72242_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).","journal-title":"Nature"},{"key":"72242_CR26","doi-asserted-by":"publisher","first-page":"e2351700","DOI":"10.1001\/jamanetworkopen.2023.51700","volume":"7","author":"WT Iams","year":"2024","unstructured":"Iams, W. T. et al. Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort. JAMA Netw. Open 7, e2351700 (2024).","journal-title":"JAMA Netw. Open"},{"key":"72242_CR27","doi-asserted-by":"publisher","first-page":"726492","DOI":"10.3389\/fimmu.2021.726492","volume":"12","author":"CR Stoltzfus","year":"2021","unstructured":"Stoltzfus, C. R. et al. Multi-parameter quantitative imaging of tumor microenvironments reveals perivascular immune niches associated with anti-tumor immunity. Front. Immunol. 12, 726492 (2021).","journal-title":"Front. Immunol."},{"key":"72242_CR28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol. 38, 395\u2013405 (2020).","journal-title":"J. Clin. Oncol."},{"key":"72242_CR29","doi-asserted-by":"publisher","first-page":"e000642","DOI":"10.1136\/jitc-2020-000642","volume":"8","author":"JN Graff","year":"2020","unstructured":"Graff, J. N. et al. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. J. Immunother. Cancer 8, e000642 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"72242_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","volume":"82","author":"EY Yu","year":"2022","unstructured":"Yu, E. Y. et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study. Eur. Urol. 82, 22\u201330 (2022).","journal-title":"Eur. Urol."},{"key":"72242_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.eururo.2022.08.005","volume":"83","author":"EY Yu","year":"2023","unstructured":"Yu, E. Y. et al. Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort A study. Eur. Urol. 83, 15\u201326 (2023).","journal-title":"Eur. Urol."},{"key":"72242_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57009-z","volume":"16","author":"S Goswami","year":"2025","unstructured":"Goswami, S. et al. Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial. Nat. Commun. 16, 1846 (2025).","journal-title":"Nat. Commun."},{"key":"72242_CR33","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.cell.2024.10.042","volume":"188","author":"L Onder","year":"2025","unstructured":"Onder, L. et al. Fibroblastic reticular cells generate protective intratumoral T cell environments in lung cancer. Cell 188, 430\u2013446 e420 (2025).","journal-title":"Cell"},{"key":"72242_CR34","doi-asserted-by":"crossref","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","DOI":"10.1186\/1471-2105-14-7"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72242-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72242-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72242-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:50:15Z","timestamp":1784069415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72242-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72242"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72242-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.S. reports consulting\/advisory fees from Achelois, Affini-T Therapeutics, Apricity, Asher Biotherapeutics, BioAlta, Candel Therapeutics, Carisma Therapeutics, Catalio, Codiak BioSciences, C-Reveal Therapeutics, Dragonfly Therapeutics, Earli, Enable Medicine, Glympse, Henlius, Hummingbird, ImaginAb, Infinity Pharmaceuticals, InterVenn Biosciences, Lava Therapeutics, Lytix Biopharma, Marker Therapeutics, Oncolytics, PBM Capital, Phenomic AI, Polaris, Trained Therapeutix, Two Bear Capital, and Xilis; stock options and other ownership interests in Achelois, Adaptive Biotechnologies, Affini-T Therapeutics, Apricity, BioAlta, BioNTX, Candel Therapeutics, Catalio, Codiak Biosciences, Dragonfly Therapeutics, Earli, Enable Medicine, Glympse, Hummingbird, ImaginAb, Infinity Pharmaceuticals, InterVenn Biosciences, JSL Health, Lava Therapeutics, Lytix Biopharma, Marker therapeutics, Oncolytics, PBM Capital, Phenomic AI, Polaris, Sporos, Time BioVentures, Trained Therapeutix, and Two Bear Capital; and patent license with Jounce. M.Kr. has no relationships to disclose. F.S. reports consulting\/advisory fees from AAA\/Novartis, Astellas Pharma, AstraZeneca, Bayer, Janssen Oncology, Merck, Myovant, Pfizer, Sanofi and Tolmar; research funding (institution) from AAA\/Novartis, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb (BMS), Janssen, Merck, Myovant, Pfizer, and Sanofi; and honoraria from AAA\/Novartis, AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, Janssen Oncology, Merck, Myovant, Pfizer, and Sanofi. D.C. reports personal fees from Astellas Pharma, AstraZeneca, BMS, GSK, Ipsen, Janssen, MSD, Novartis, Pfizer, and Roche; and financial institutional relationships with Astellas Pharma, AstraZeneca, Bayer, BMS, Clovis, Eisai, Exelixis, GSK, Ipsen, Janssen, Lilly, MSD, Pfizer, QED Therapeutics, and Roche. J.B. reports consulting\/advisory fees from BMS, Eisai, EUSA Pharma, Ipsen, Merck KGaA, MSD Oncology, Pfizer, and Roche; speakers\u2019 bureau fees from BMS, Ipsen, Merck KGaA, MSD Oncology, and Pfizer; and research funding from Astellas Pharma, BMS, Exelixis, Ipsen, MSD Oncology, Novartis, Pfizer, Roche, and Seattle Genetics. M.Kw. reports personal fees from Janssen, Novartis, and Roche; and clinical trial participation with AstraZeneca, Bayer, BMS, Brigene, Hengrui, Janssen Cilag, MSD, Roche, and Shanghai Jinshu. A.P. reports consulting\/advisory or personal fees from Boston Gene, Clovis, Exelixis, Gerson Lehrman Group, Guidepoint, Janssen, and PRIME; research funding from AstraZeneca, BMS, Clovis, Laekna, PRIME, Progenics, and Xencor; and other grants from the Department of Defense, National Cancer Institute, Phi Beta Psi Charity Trust Research Organization, and Prostate Cancer Foundation. G.P. reports consulting\/advisory fees or personal fees from ACCORD Healthcare Italia srl, Amgen, Astellas Pharma, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eisai, Eli Lilly, Ipsen, Janssen, Janssen-Cilag, Menarini Group, Merck, MSD, Orche, Pfizer, and Telix Pharmaceuticals Limited; and other institutional research grants from Gilead, Ipsen, Janssen, and MSD. P.W. reports consulting\/advisory fees from Astellas Pharma, Bayer, BMS, Janssen-Cilag, Merck, and Pfizer; and personal fees from Astellas Pharma, Bayer, BMS, Janssen-Cilag, Merck, MSD, and Pfizer. S.K. has no relationships to disclose. C.T. reports consulting\/advisory fees from Astellas Pharma, Bayer, BMS, Janssen, and Merck. J.\u00c1.A.A. reports consulting\/advisory fees from Astellas Pharma, AstraZeneca, Bayer, BMS, Eisai, Janssen-Cilag, Merck, MSD Oncology, Novartis, and Pfizer; personal fees from Astellas Pharma, BMS, and Pfizer; and research funding (institution) from BMS. S.L.M. reports speakers\u2019 bureau fees from BMS; and research funding from BMS and Roche\/Genentech. S.H. has no relationships to disclose. G.D. reports consulting\/advisory fees from Astellas Pharma, Bayer, BMS, MSD Oncology, Pfizer, and Sanofi\/Aventis; and personal fees from Astellas Pharma. J.I.D.M. has no relationships to disclose. C.K. has no relationships to disclose. S.K.S. reports personal fees from Baird Boxer Capital, Breaking Data, Intellisphere LLC, NoeticInsight, SurvivorNet, The Clinical Comms Group, and Third Bridge; nonfinancial support from AstraZeneca; personal fees and nonfinancial support from Arcus Biosciences, BMS, DAVA Oncology, Dendreon, HERVolution, Johnson & Johnson, Kahr Medical Ltd, Kiniksa Pharmaceuticals, Merck, Novartis, Pfizer, Portage, Regeneron, Rondo Therapeutics, and Society for Immunotherapy of Cancer; and personal fees and ownership interests from Apricity Health and Vicero. S.B. has no relationships to disclose. S.J. has no relationships to disclose. B.A.S. reports honoraria from Cancer Experts Now, Curio Science, Cardinal Health; consulting\/advisory fees from Amgen, Bayer, Johnson & Johnson, Merck, and Pfizer; research funding (to institution) from Regeneron and Amgen; research funding (to individual) from ASCO-Conquer Cancer Foundation, Prostate Cancer Foundation, and Cancer Research Institute; and travel support from Merck, Curio Science, and Cardinal Health. A.L., S.G., and A.C. are employees of BMS; V.F., N.P.A., Y.W., and J.M.D. were employees of BMS at the time of the study and data analysis and interpretation. R.K.P. reports consulting\/advisory fees from Astellas Pharma, Bayer, Blue Earth Diagnostics, BMS, Dendreon, EMD Serono, Exelixis, Genomic Health, Merck, Pfizer, and Sanofi; speakers\u2019 bureau fees from Bayer, Dendreon, Merck, and Sanofi; personal fees from Genentech\/Roche; research funding from BMS, Exelixis, and Pharmacyclics (institution) and Janssen Oncology (personal); IP licensing and licensing fees from Tempus; and IP licensing and ownership interest from Pixie Biosciences, Inc.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6216"}}